Atara Q1 net loss narrows to $31.8M; tab-cel BLA on track for Q2 2024 submission

Atara Biotherapeutics, Inc.

2024-Q1 EPS reported -$0.23 revenue$27,357,000

Q1 2024 net loss of $31.8M ($0.23/sh) vs $74.8M ($0.72/sh) in Q1 2023; revenue rose to $27.4M from $1.2M on Pierre Fabre partnership.
Cash, equivalents, ST investments $46.2M plus AR $35.8M; expects funding into 2027 with potential $80M in tab-cel BLA milestones.
BLA submission for tab-cel in EBV+ PTLD planned Q2 2024; pivotal data showed 48.8% ORR (p<0.0001); Swissmedic approval received.
ATA3219 lupus nephritis study to start Q4 2024; initial data H1 2025; new SLE cohort without lymphodepletion also in Q4 2024.
Full-year 2024 operating expenses expected to decrease ~35% vs 2023; restructuring cut workforce by 25% to 170 employees.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atara Biotherapeutics, Inc. reported financial results for first quarter 2024.

Period: first quarter 2024
Result: reported results

Exact text from the filing

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056901

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.